Kim Dong-Hyun
Department of Life and Nanopharmaceutical Sciences and Department of Pharmacy, Kyung Hee University, Seoul, Republic of Korea
Drug Metab Dispos. 2015 Oct;43(10):1581-9. doi: 10.1124/dmd.115.063867. Epub 2015 Apr 29.
Xenobiotic metabolism involves the biochemical modification of drugs and phytochemicals in living organisms, including humans and other animals. In the intestine, the gut microbiota catalyzes the conversion of hydrophilic drugs into absorbable, hydrophobic compounds through hydroxyzation and reduction. Drugs and phytochemicals are transformed into bioactive (sulfasalazine, lovastatin, and ginsenoside Rb1), bioinactive (chloramphenicol, ranitidine, and metronidazole), and toxic metabolites (nitrazepam), thus affecting the pharmacokinetics of the original compounds. Antibiotics suppress the activities of drug-metabolizing enzymes by inhibiting the proliferation of gut microbiota. Antibiotic treatment might influence xenobiotic metabolisms more extensively and potently than previously recognized and reduce gut microbiota-mediated transformation of orally administered drugs, thereby altering the systemic concentrations of intact drugs, their metabolites, or both. This review describes the effects of antibiotics on the metabolism of drugs and phytochemicals by the gut microbiota.
异源物质代谢涉及生物体(包括人类和其他动物)对药物和植物化学物质的生化修饰。在肠道中,肠道微生物群通过羟化和还原作用将亲水性药物催化转化为可吸收的疏水性化合物。药物和植物化学物质被转化为生物活性物质(柳氮磺胺吡啶、洛伐他汀和人参皂苷Rb1)、无生物活性物质(氯霉素、雷尼替丁和甲硝唑)以及有毒代谢物(硝西泮),从而影响原始化合物的药代动力学。抗生素通过抑制肠道微生物群的增殖来抑制药物代谢酶的活性。抗生素治疗对异源物质代谢的影响可能比之前认识到的更为广泛和有力,并且会减少肠道微生物群介导的口服药物转化,从而改变完整药物及其代谢物的全身浓度,或两者皆有改变。本综述描述了抗生素对肠道微生物群药物和植物化学物质代谢的影响。